Zydus Cadila Has Received Final Approval From The Us Food And Drug Administration (Fda) To Market Mesalamine Extended-Release Capsules In The Strength Of 0.375 G.Mesalamine Extended-Release Capsules Are Indicated For The Maintenance Of Remission Of Ulcerative Colitis In Adults.The Drug Will Be Manufactured At The Group&Rsquo;S Formulation Manufacturing Facility At The Sez, Ahmedabad.The Group Now Has 320 Approvals And Has So Far Filed Over 400 Andas Since The Commencement Of The Filing Process In Fy 2003-04.
